Pharmaceutical News

RSS

Continuous wound infusion with local anesthetic reduces pain after hip surgery

In patients undergoing hip replacement surgery, using a special wound catheter to infuse local anesthetic directly into the hip joint provides significant and lasting improvements in postoperative pain control, reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

1 Feb 2012

NanoViricides files FluCide pre-IND briefing document with the FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND briefing document to the US FDA. This submission provides the required information for the Company's highly effective anti-influenza drug candidate, FluCide, in support of a pre-IND Meeting.

1 Feb 2012

Novartis' Gleevec receives FDA approval for use in patients with CD117-positive GIST

The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors.

1 Feb 2012

Crizotinib can treat ROS1-driven tumors

A report from investigators at the Massachusetts General Hospital (MGH) Cancer Center has defined the role of a recently identified gene abnormality in a deadly form of lung cancer. Tumors driven by rearrangements in the ROS1 gene represent 1 to 2 percent of non-small-cell lung cancers (NSCLC), the leading cause of cancer death in the U.S.

1 Feb 2012

Vertex receives FDA approval for Kalydeco to treat rare form of CF

The U.S. Food and Drug Administration today approved Kalydeco (ivacaftor) for the treatment of a rare form of cystic fibrosis (CF) in patients ages 6 years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene.

1 Feb 2012

FDA approves Lannett's supplemental ANDA for Phentermine HCl to treat obesity

Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its supplemental Abbreviated New Drug Application (ANDA) for Phentermine HCl Capsules, 15 mg.

1 Feb 2012

Milestone for Starpharma's drug delivery program

Starpharma Holdings today released animal data which demonstrated that its dendrimer-docetaxel formulation applying Starpharma’s dendrimer technology to the leading chemotherapy drug docetaxel was significantly more efficacious than docetaxel (Taxotere®) in a breast cancer model.

1 Feb 2012

FDA faces legal attack over alleged spying on whistleblowers

A latest lawsuit filed in federal court has accused the Food and Drug Administration (FDA) of electronically spying on whistleblowers who alerted the Obama administration and Congress of alleged misconduct in the agency, particularly relating to what they claim was the push to approve unsafe and ineffective medical devices.

31 Jan 2012

Roche’s skin cancer drug Erivedge gets FDA nod

The Food and Drugs Administration (FDA) this Monday approved a pill that treats the most common type of skin cancer, basal cell carcinoma.

31 Jan 2012

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.

31 Jan 2012

Bioton and Actavis form joint venture

Actavis and Bioton announced today that they have formed a joint venture company for the development and registration of insulins, including analogue insulins.

31 Jan 2012

Indoco, DSM sign agreement for commercial cooperation for eight APIs

Royal DSM N.V., today announced the signing of an agreement with Indoco Remedies Limited, Mumbai, India, for commercial cooperation for eight Active Pharmaceutical Ingredients (APIs). The alliance came into effect in January 2012.

31 Jan 2012

Takeda returns POSIDUR development and commercialization rights to DURECT

DURECT Corporation today reported that Takeda has given notice that it is returning its development and commercialization rights to POSIDUR in Europe and their other licensed territories.

31 Jan 2012

CDC models show scaling up ART for HIV treatment can save money over time

During a webinar Thursday hosted by the Health Global Access Project, AVAC, and amfAR, John Blandford, chief of CDC's Division of Global HIV/AIDS Health Economics, Systems and Integration Branch, presented findings showing "that scaling up antiretroviral therapy (ART) for HIV/AIDS treatment and prevention in the developing world not only saves lives, but saves money too," the Center for Global Health Policy's "Science Speaks" blog reports.

31 Jan 2012

Neutra closer to delivering Pure Plus weight-loss supplement

Neutra Corp., an emerging provider of innovative nutraceuticals, announced today that it is one step closer to delivering its revolutionary Pure Plus weight-loss supplement to market.

31 Jan 2012

FDA approves Genentech's Erivedge for treatment of BCC

Genentech, a member of the Roche Group, today announced that Erivedge (vismodegib) capsule was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.

31 Jan 2012

Genentech receives FDA approval for Erivedge to treat basal cell carcinoma

Today, Erivedge (vismodegib) was approved by the U.S. Food and Drug Administration to treat adult patients with basal cell carcinoma, the most common type of skin cancer. The drug is intended for use in patients with locally advanced basal cell cancer who are not candidates for surgery or radiation and for patients whose cancer has spread to other parts of the body.

31 Jan 2012

Watson plans to establish Global R&D Technology Center in North Brunswick

Watson Pharmaceuticals, Inc. today announced plans to establish a Global R&D Technology Center in North Brunswick, New Jersey.

30 Jan 2012

FDA approves Baxter's TISSEEL for general hemostasis in surgery

Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved TISSEEL [Fibrin Sealant] to include general hemostasis in surgery when control of bleeding by standard surgical techniques is ineffective or impractical.

From Baxter International Inc. 30 Jan 2012

Allos seeks re-examination of EMA CHMP opinion on FOLOTYN for PTCL

Allos Therapeutics, Inc. today announced that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in January by the EMA's Committee For Medicinal Products for Human Use (CHMP) for conditional approval of FOLOTYN (pralatrexate injection) for the treatment of patients with peripheral T-cell lymphoma (PTCL) whose disease has progressed after at least one prior systemic therapy.

30 Jan 2012